TLSA NASDAQ
Tiziana Life Sciences Ltd
1W: +10.9%
1M: +20.2%
3M: -4.3%
YTD: -30.0%
1Y: -42.6%
3Y: +67.2%
5Y: -25.8%
$1.12
-0.02 (-1.75%)
Weekly Expected Move ±20.0%
$1
$1
$1
$1
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$16M
+12.2% ▲
Net Income
-$12M
+32.9% ▲
EPS (Diluted)
$-0.22
+35.3% ▲
EBITDA
-$17M
+3.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $6M | $13M | $13M | $8M | $5M |
| SG&A Expenses | $13M | $855K | $0 | $0 | $0 |
| Operating Expenses | $28M | $27M | $15M | $18M | $16M |
| Operating Income | -$28M | -$27M | -$15M | -$18M | -$16M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $320K | $176K | $7K | $10K | $6K |
| Income Before Tax | -$28M | -$27M | -$15M | -$17M | -$17M |
| Tax Expense | -$2M | -$3M | $0 | $449K | -$5M |
| Net Income | -$26M | -$23M | -$15M | -$18M | -$12M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.54 | $-0.48 | $-0.30 | $-0.34 | $-0.22 |
| EBITDA | -$28M | -$26M | -$15M | -$17M | -$17M |
| Shares Outstanding | 49M | 49M | 51M | 51M | 53M |